Glecaprevir/Pibrentasvir: First Global Approval.

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) infection remains a significant global health concern.
• Development of direct-acting antivirals (DAAs) has revolutionized HCV treatment.
• Need for pan-genotypic and highly effective HCV therapies persists.

Purpose of the Study:

• To summarize the development milestones of glecaprevir/pibrentasvir.
• To highlight the regulatory approvals for chronic HCV infection.
• To detail the efficacy and safety profile of the fixed-dose combination.

Main Methods:

• Glecaprevir (HCV NS3/4A protease inhibitor) and pibrentasvir (HCV NS5A inhibitor) were developed as a fixed-dose combination.
• Clinical trials evaluated the efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV genotypes 1-6.
• Regulatory submissions were made to the European Medicines Agency (EMA) and US Food and Drug Administration (FDA).

Main Results:

• Glecaprevir/pibrentasvir demonstrated high sustained virologic response rates across major HCV genotypes.
• The fixed-dose combination was approved by the EMA for all major genotypes (1-6) in adults.
• The US FDA approved glecaprevir/pibrentasvir for specific patient populations, including those with compensated cirrhosis and treatment-experienced patients.

Conclusions:

• Glecaprevir/pibrentasvir provides an effective and well-tolerated treatment option for chronic HCV infection.
• The drug's pan-genotypic activity simplifies treatment selection for patients with diverse HCV genotypes.
• Regulatory approvals in the EU and USA mark a significant advancement in HCV management.